Armata Pharmaceuticals, Inc.
NYSE American ARMP
Armata Pharmaceuticals, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2024: USD -37.73 M
-
Armata Pharmaceuticals, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -49.80 M, a -62.78% change year over year.
-
Armata Pharmaceuticals, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -30.59 M, a -43.78% change year over year.
-
Armata Pharmaceuticals, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -21.28 M, a -44.78% change year over year.
-
Armata Pharmaceuticals, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -14.70 M, a 3.82% change year over year.
| Date | Operating Cash Flow | Net Cash Used For Investing Activities | Net Cash Used Provided By Financing Activities | Dividends Paid |
|---|
| CEO | Dr. Deborah L. Birx M.D. |
| IPO Date | May 20, 1994 |
| Location | United States |
| Headquarters | 4503 Glencoe Avenue |
| Employees | 66 |
| Sector | Health Care |
| Industries | |
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
Past 5 years
USD 2.13
StockViz Staff
January 15, 2025
Any question? Send us an email